Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Insights - The company reported a revenue of 2.45 billion yuan for Q1-Q3 2025, representing a year-on-year growth of 25.5%. The net profit attributable to shareholders was 240 million yuan, up 2.13% year-on-year. In Q3 alone, revenue reached 690 million yuan, a 14.3% increase year-on-year, while net profit attributable to shareholders was 69.48 million yuan, growing by 11.6% year-on-year. However, the non-recurring net profit saw a decline of 20% year-on-year [2][4]. Summary by Sections Revenue Performance - For Q3 2025, the company achieved revenue of 1.5 billion yuan from eye care products, 3.1 billion yuan from skincare, 0.7 billion yuan from cleansing products, and 1.5 billion yuan from beauty products, with year-on-year growth rates of 20%, 42%, 23%, and -27% respectively. The main brand is expected to maintain good growth, while the beauty category is under pressure [9]. Profitability Analysis - In the first three quarters of 2025, the net profit margin decreased by 2.3 percentage points to 10%. This was attributed to a slight increase in gross margin by 0.3 percentage points to 74.9%, while sales, management, and R&D expense ratios increased by a total of 3.1 percentage points [9]. Investment Recommendations - The company is expected to continue its large product strategy, with the main brands, Marubi and Lianhuo, maintaining growth momentum. New products such as the "Little Gold Needle" cream and mask are being introduced, indicating significant growth potential. The forecasted EPS for 2025-2027 is 0.95, 1.12, and 1.29 yuan per share respectively, with a "Buy" rating maintained [9].

Group 1 - The report highlights the significant achievements in the recent China-US trade talks, with the US agreeing to suspend certain tariffs on Chinese goods, which may positively impact trade dynamics [7] - The macroeconomic policy emphasizes the importance of expanding domestic demand and improving living standards, as outlined in the "15th Five-Year Plan" [5][6] - The report notes a shift in export growth, with October exports showing a decline of 1.1% year-on-year, influenced by high base effects from the previous year [11][12] Group 2 - The report discusses the rebalancing between technology and cyclical sectors, suggesting that both will play significant roles in the market moving forward [17][20] - It identifies the satellite industry as a strategic investment opportunity, driven by large market potential, strong policy support, and technological advancements [23][24] - The report indicates that the REIT market is showing resilience, with the recent listing of the CITIC Construction Investment Shenyang International Software Park REIT, which is expected to attract investment due to its high dividend yield [65][66]

Core Insights - The retail industry is experiencing a shift from value preservation to emotional value, with a focus on high-growth segments for investment opportunities [5][28] - The report maintains a positive outlook on the retail sector, emphasizing the importance of consumer insights and differentiated product offerings [5][28] Retail Market Overview - The retail index reported a slight increase of 0.31% during the week of November 3 to November 7, 2025, underperforming the Shanghai Composite Index, which rose by 1.08% [7][16] - Year-to-date, the retail index has increased by 4.20%, lagging behind the Shanghai Composite Index's 19.27% growth [16][20] Investment Strategy for 2026 - The investment strategy highlights four main themes: 1. **Gold and Jewelry**: Focus on high-end and fashionable gold segments, with recommendations for brands like Lao Pu Gold and Chao Hong Ji [5][48] 2. **Retail E-commerce**: Emphasize the transformation of offline retail to enhance service and experience, with key players like Yonghui Supermarket and Ai Ying Shi [5][48] 3. **Cosmetics**: Target domestic brands that capture emotional value and innovate on safety ingredients, recommending brands like Juzi Biological and Pechoin [5][49] 4. **Medical Aesthetics**: Focus on differentiated product manufacturers and expanding medical institutions, with recommendations for brands like Ai Mei Ke and Ke Di-B [5][49] Sector Performance - The jewelry sector is undergoing significant changes due to rising gold prices and a decline in traditional wedding markets, leading to the emergence of brands with strong consumer insights [5][29] - The cosmetics sector is seeing a rise in domestic brands leveraging cultural roots and emotional value to capture market share [5][41] Company-Specific Insights - **Chao Hong Ji**: Reported a revenue increase of 28.4% year-on-year for the first three quarters of 2025, with a notable performance in Q3 [54] - **Yonghui Supermarket**: Experienced a revenue decline of 22.2% year-on-year for the first three quarters of 2025, but is undergoing significant transformation [50] - **Juzi Biological**: Achieved a revenue growth of 21.7% year-on-year for the first half of 2025, focusing on collagen products [50]

Core Points - The company's profit distribution plan was approved at the first extraordinary general meeting of shareholders on September 19, 2025 [1] - The distribution will be based on a total share capital of 401,000,000 shares, with a cash dividend of 0.25 RMB per share, totaling 100,250,000 RMB [2] - The cash dividends will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [1][2] Distribution Plan - The cash dividend of 0.25 RMB per share is inclusive of tax, and the total cash dividend distribution amounts to 100,250,000 RMB [2] - The distribution will not include stock dividends or capital increases [2] - Shareholders who hold shares for more than one year will be exempt from individual income tax on the dividend, while those holding for one year or less will have tax withheld upon transfer [3] Taxation Details - Individual shareholders holding shares for less than one month will incur a 20% tax on dividends, while those holding for one month to one year will incur a 10% tax [3] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.225 RMB per share [4] - Hong Kong investors through the Stock Connect will also face a 10% withholding tax, leading to a net dividend of 0.225 RMB per share [4] Contact Information - For inquiries regarding the profit distribution, shareholders can contact the board office at 020-66378685 [5]

Core Viewpoint - Guangdong Marubi Biotechnology Co., Ltd. (hereinafter referred to as "Marubi") has been warned by the Guangdong Securities Regulatory Bureau due to irregularities in financial accounting and management of raised funds, indicating significant internal management shortcomings [1][2]. Financial Irregularities - Marubi's financial accounting issues include inaccurate revenue recognition, incorrect construction project accounting, and erroneous reporting of related accounting items [1]. - The company used raised funds for cash management without proper disclosure of investment returns and related information [1]. - Following the regulatory warning, Marubi's chairman, secretary of the board, and CFO received warning letters from the regulatory authority [1]. Financial Performance - In the first half of 2025, Marubi's adjusted revenue was 1.765 billion yuan, a decrease of 4.5468 million yuan compared to previous adjustments, while the net profit attributable to shareholders was 174 million yuan, down by 11.3297 million yuan [2]. - For Q3 2025, Marubi reported revenue of 686 million yuan, a year-on-year increase of 14.28%, and a net profit of 69.4816 million yuan, up 21.16% [4]. - In the first three quarters of 2025, the company achieved revenue of 2.45 billion yuan, a growth of 25.51%, with a net profit of 244 million yuan, increasing by 2.13% [4]. Market Position and Competition - Marubi's main brand, Marubi, is positioned in the mid-to-high-end market, contributing 2.055 billion yuan to the company's total revenue of 2.97 billion yuan in 2024, accounting for 69.24% [4]. - Compared to competitors like Proya and Shiseido, Marubi faces challenges due to its mid-to-high-end pricing strategy and a smaller market size for eye creams [5]. - The company has been slower in transitioning to online sales channels compared to peers, which may hinder its competitive edge [5]. R&D Investment - In the first half of 2025, Marubi's R&D expenses were 39.9648 million yuan, representing 2.26% of total revenue, which is in line with industry averages but lower than leading competitors [6]. - The company aims to transition to a biotechnology-focused beauty brand, but its current R&D investment does not meet the necessary levels for such a transformation [6]. Future Outlook - The company's future development hinges on rebuilding trust in corporate governance and internal controls, enhancing R&D capabilities, and creating new growth engines to satisfy investors [6].

Core Points - The company announced a cash dividend distribution of 0.25 CNY per share for the first half of 2025, approved at the shareholders' meeting on September 19, 2025 [2][4] - The total cash dividend to be distributed amounts to 100,250,000 CNY, based on a total share capital of 401,000,000 shares [4] Distribution Plan - The distribution is for the first half of 2025 and applies to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the equity registration [3] - The cash dividend will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited, with specific arrangements for shareholders who have completed designated transactions [5][6] - No bonus shares or capital increases will be issued as part of this distribution [6] Taxation Details - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.25 CNY per share [9] - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated and deducted upon the sale of shares [9] - For qualified foreign institutional investors (QFII) and Hong Kong investors, a 10% withholding tax applies, resulting in a net distribution of 0.225 CNY per share [10][11]

Market Overview - The cosmetics sector experienced a decline of 0.24% on November 7, with Jiaheng Jiahua leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Individual Stock Performance - Qing Song Co. (300132) saw an increase of 2.61%, closing at 7.46 with a trading volume of 332,800 shares and a turnover of 246 million [1] - Jiaheng Jiahua (300955) led the decline with a drop of 4.99%, closing at 34.85 with a trading volume of 36,400 shares and a turnover of 129 million [2] - Other notable performers include: - Wanmei Biological (603983) up 0.78% to 33.56 [1] - Shuiyang Co. (300740) up 0.62% to 20.96 [1] - Furuida (600223) down 0.52% to 7.77 [1] Capital Flow Analysis - The cosmetics sector saw a net outflow of 43.89 million from institutional investors, while retail investors experienced a net inflow of 13.79 million [2] - Notable capital flows include: - Qing Song Co. (300132) had a net inflow of 37.12 million from institutional investors [3] - Jiaheng Jiahua (300955) experienced a net outflow of 11.10 million from institutional investors [3] - Furuida (600223) had a significant net outflow of 7.78 million from institutional investors [3]

证券代码：603983 证券简称：丸美生物 公告编号：2025-034 广东丸美生物技术股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 9 月 19 日的2025年第一次临时股东大会审 议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 重要内容提示： 每股分配比例 A 股每股现金红利0.25元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/11/13 | － | 2025/11/14 | 2025/11/14 | 差异化分红送转： 否 1. 发放年度：2025年半年度 2. 分派对象： 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股 东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本401, ...

Group 1 - The company, Marubi Biotechnology (603983.SH), announced a cash dividend distribution of 0.25 yuan per share (including tax), totaling 100 million yuan (including tax) based on a total share capital of 401 million shares prior to the distribution [1] - The record date for the dividend distribution is set for November 13, 2025, and the ex-dividend date is November 14, 2025 [1]

Investment Rating - The industry investment rating is "Outperform the Market" with an expected relative increase of over 10% in the next six months [25]. Core Insights - The fund allocation ratio for the beauty and personal care industry decreased in Q3 2025, with a total market capitalization of 284.799 billion yuan, reflecting a 2.79% increase from Q2 2025. The fund's total holdings in the beauty and personal care sector amounted to 6.796 billion yuan, resulting in a fund allocation ratio of 0.20%, which is a decrease of 0.12 percentage points from Q2 2025, indicating a continued underweight position [2][11]. - The medical beauty sub-sector is currently in an overweight position, while personal care and cosmetics are underweight. The fund allocation ratio for personal care products was 0.04% in Q3 2025, down 0.04 percentage points from the previous quarter. The cosmetics sector also saw a decline, maintaining a fund allocation ratio of 0.04% in Q3 2025, down 0.02 percentage points [3][16]. - The top three stocks by fund holding in Q3 2025 are Jinbo Biological, Aimeike, and Baiya Shares, with a total holding ratio of 0.07%, which is a decrease of 0.04 percentage points from Q2 2025 [4][18]. Summary by Sections Industry Overview - In Q3 2025, the beauty and personal care industry fund allocation ratio decreased to 0.20%, with an underweight ratio of -0.09%, indicating a continued low allocation [2][11]. Sub-sector Analysis - Medical Beauty: The fund allocation ratio peaked at 0.53% in Q4 2022 but has since declined to 0.12% in Q3 2025, with an overweight ratio of 0.03% in Q2 2025 [3][16]. - Personal Care: The fund allocation ratio was at a historical low from Q3 2021 to Q3 2022, with a slight recovery post-Q4 2022. The current ratio is 0.04%, indicating a shift from positive to negative overweight [3][16]. - Cosmetics: The fund allocation ratio has been declining since Q3 2022, currently at 0.04%, with an overweight ratio of -0.09% [3][16]. Stock Holdings - The top three stocks in the beauty and personal care sector by fund holding in Q3 2025 are Jinbo Biological (0.0254%), Aimeike (0.0195%), and Baiya Shares (0.0051%), all showing a decline in holding ratios compared to Q2 2025 [4][21]. Investment Recommendations - The report suggests focusing on cosmetics and medical beauty sectors due to significant demand potential in the long term, driven by the "beauty economy." It also highlights the importance of compliance and strong R&D capabilities in personal care products [5][24].